Gefitinib impurity 2

Gefitinib impurity 2 is the impurity of Gefitinib. Gefitinib (ZD1839; HY-50895) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy. Gefitinib has antitumour activity[1][2].

Product Specifications

CAS Number

[246512-44-7]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Field of Research

Others; Cancer

Assay Protocol

https://www.medchemexpress.com/gefitinib-impurity-2.html

Purity

99.56

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N)C1=CC(OCCCN2CCOCC2)=C(OC)C=C1N

Molecular Formula

C15H23N3O4

Molecular Weight

309.37

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

References & Citations

[1] Wakeling AE, et al. ZD1839: an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002 Oct 15;62 (20) :5749-54.|[2]Pedersen MW, et al. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer. 2005 Oct 17;93 (8) :915-23.